We are thrilled to share that Biocytogen will attend the T-Cell Engager for Autoimmune Disease Summit from October 27th - 29th, in Boston, MA. Delve into technical discussions with researchers, clinical developers, and industry leaders to gain insights into the latest advances in autoimmune T-cell engager therapies. Come connect with our team at booth #2 to learn how we can accelerate your TCE pipeline. From antibody discovery with our AI-powered RenSuper Workstation to highly translatable in vivo validation with our humanized BioMice models, we provide the comprehensive end-to-end solutions you need.
What is the T-Cell Engager for Autoimmune Disease Summit?
The T-Cell Engager for Autoimmune Disease Summit examines the scientific and clinical challenges of developing T-cell engager therapies for autoimmune conditions. It serves as a premier forum for case studies, panel discussions, and workshops exploring new engager designs, selective targeting of disease-driving immune cells, and approaches to improving safety and treatment durability.
Event Overview
Date: October 27th - 29th, 2026
Venue: The Colonnade Hotel, 120 Huntington Ave, Boston, MA 02116
Booth: 2
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
